beta-alanine has been researched along with Acute Disease in 14 studies
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE." | 9.19 | Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014) |
| "Acute carpal tunnel syndrome is an uncommon diagnosis most often related to blunt trauma requiring immediate surgical decompression to avoid serious sequelae." | 5.38 | Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran. ( Mandel, RJ; Sibley, PA, 2012) |
| "Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE." | 5.19 | Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014) |
| "All NOACs are at least as effective as warfarin for stroke prevention in patients with nonvalvular AF, and are at least as safe in terms of bleeding risk according to 3 large trials." | 4.90 | Approach to the new oral anticoagulants in family practice: part 1: comparing the options. ( Bell, AD; Douketis, J; Eikelboom, J; Liew, A, 2014) |
| "Dabigatran is an oral direct thrombin inhibitor that is Food and Drug Administration-approved for prevention of stroke in patients with atrial fibrillation." | 3.79 | Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. ( Hallows, KR; Henry, BL; Maw, TT; Nolin, TD; Pastor-Soler, NM; Singh, T; Unruh, ML, 2013) |
| "Isovaline reduced responses in mouse pain models without producing acute toxicity, possibly by enhancing receptor modulation of nociceptive information." | 3.76 | Analgesic properties of the novel amino acid, isovaline. ( Chung, CC; MacLeod, BA; Puil, E; Ries, CR; Schwarz, SK; Wang, JT, 2010) |
| " They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring." | 2.50 | Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. ( Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014) |
| "Acute carpal tunnel syndrome is an uncommon diagnosis most often related to blunt trauma requiring immediate surgical decompression to avoid serious sequelae." | 1.38 | Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran. ( Mandel, RJ; Sibley, PA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, T | 1 |
| Maw, TT | 1 |
| Henry, BL | 1 |
| Pastor-Soler, NM | 1 |
| Unruh, ML | 1 |
| Hallows, KR | 1 |
| Nolin, TD | 1 |
| Schulman, S | 1 |
| Kakkar, AK | 1 |
| Goldhaber, SZ | 2 |
| Schellong, S | 1 |
| Eriksson, H | 1 |
| Mismetti, P | 1 |
| Christiansen, AV | 1 |
| Friedman, J | 1 |
| Le Maulf, F | 1 |
| Peter, N | 1 |
| Kearon, C | 1 |
| Fontana, P | 1 |
| Bounameaux, H | 1 |
| Douketis, J | 2 |
| Bell, AD | 2 |
| Eikelboom, J | 2 |
| Liew, A | 2 |
| Bamps, S | 1 |
| Decramer, T | 1 |
| Vandenbussche, N | 1 |
| Verhamme, P | 1 |
| Thijs, V | 1 |
| Van Loon, J | 1 |
| Theys, T | 1 |
| Siddon, AJ | 1 |
| Rinder, HM | 1 |
| Hendrickson, JE | 1 |
| Tormey, CA | 1 |
| Wilson, ZS | 1 |
| Ahn, LB | 1 |
| Serratelli, WS | 1 |
| Belley, MD | 1 |
| Lomas-Neira, J | 1 |
| Sen, M | 1 |
| Lefort, CT | 1 |
| MacLeod, BA | 1 |
| Wang, JT | 1 |
| Chung, CC | 1 |
| Ries, CR | 1 |
| Schwarz, SK | 1 |
| Puil, E | 1 |
| Sibley, PA | 1 |
| Mandel, RJ | 1 |
| Siegal, DM | 1 |
| Crowther, MA | 1 |
| Yoshinaga, A | 1 |
| Nakagomi, K | 1 |
| Goto, S | 1 |
| Kunishima, H | 1 |
| Seki, R | 1 |
| Iwabuchi, T | 1 |
| Nakamura, T | 1 |
| Ishida, N | 1 |
| Takagi, T | 1 |
| Shimada, J | 1 |
| Sekiguchi, T | 1 |
| Okamoto, T | 1 |
| Ohara, K | 1 |
| Kouzan, H | 1 |
| Nishioka, A | 1 |
| Suzue, T | 1 |
| Matsuda, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran- a Cross-Sectional Assessment of RE-COVER Study Patients[NCT03050138] | 351 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatm[NCT00680186] | Phase 3 | 2,589 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following In[NCT00291330] | Phase 3 | 2,564 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Frequency of patients with possible clinically significant abnormalities. (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase | AST decrease | ALT increase | ALT decrease | Bilirubin increase | Bilirubin decrease | |
| Dabigatran 150 mg | 29 | 0 | 31 | 0 | 8 | 0 |
| Warfarin | 27 | 0 | 40 | 0 | 6 | 0 |
Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 25 | 29 |
| Warfarin | 25 | 26 |
VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events. (NCT00680186)
Timeframe: From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 3 | 3 |
| Warfarin | 0 | 0 |
Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings. (NCT00680186)
Timeframe: From first intake of study drug to last contact date
| Intervention | participants (Number) | |
|---|---|---|
| During intake of study drug | After stopping study drug | |
| Dabigatran 150 mg | 3 | 2 |
| Warfarin | 0 | 1 |
"Major bleeding events (MBE) are defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) are defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout
| Intervention | participants (Number) | ||
|---|---|---|---|
| MBE | MBE and/or CRBE | Any bleeding event | |
| Dabigatran 150 mg | 15 | 64 | 200 |
| Warfarin | 22 | 102 | 285 |
Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 25 | 28 |
| Warfarin | 17 | 17 |
Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 8 | 10 |
| Warfarin | 13 | 15 |
Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 7 | 9 |
| Warfarin | 13 | 15 |
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 30 | 34 |
| Warfarin | 28 | 30 |
VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 51 | 57 |
| Warfarin | 48 | 51 |
Frequency of patients with possible clinically significant abnormalities. (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase | AST decrease | ALT increase | ALT decrease | Bilirubin increase | Bilirubin decrease | |
| Dabigatran 150 mg | 21 | 0 | 26 | 0 | 7 | 0 |
| Warfarin | 22 | 0 | 38 | 0 | 13 | 0 |
Any deaths which occured from randomisation to end of post treatment period. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 21 | 25 |
| Warfarin | 21 | 25 |
"VTE - related deaths which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 1 | 1 |
| Warfarin | 3 | 3 |
"Any ACS occurring during the conduct of the study (centrally adjudicated as definite).~Counts of patients having a centrally adjudicated definite ACS during intake of active study drug, after stopping active study drug and before or without intake of active study drug, according to treatment group.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: From first intake of study drug to end of study conduct
| Intervention | participants (Number) | ||
|---|---|---|---|
| During intake of active study drug | After stopping active study drug | Before/without intake of active study drug | |
| Dabigatran 150 mg | 5 | 4 | 2 |
| Warfarin | 3 | 2 | 0 |
"Major bleeding events (MBE) were defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) was defined as~spontaneous skin hematoma >=25 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding events | MBE and/or CRBE | Any bleeding events | |
| Dabigatran 150 mg | 20 | 71 | 207 |
| Warfarin | 24 | 111 | 280 |
"Symptomatic DVT which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 16 | 17 |
| Warfarin | 18 | 22 |
"Symptomatic non-fatal PE which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 13 | 16 |
| Warfarin | 7 | 8 |
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)
| Intervention | Participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 30 | 34 |
| Warfarin | 27 | 32 |
"VTE or any death which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
| Intervention | Participants (Number) | |
|---|---|---|
| Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
| Dabigatran 150 mg | 48 | 55 |
| Warfarin | 44 | 53 |
4 reviews available for beta-alanine and Acute Disease
| Article | Year |
|---|---|
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, P | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; | 2014 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alani | 2013 |
[A case of acute spongiositis with diabetes mellitus].
Topics: Acute Disease; beta-Alanine; Diabetes Complications; Drug Therapy, Combination; Humans; Male; Middle | 2002 |
2 trials available for beta-alanine and Acute Disease
| Article | Year |
|---|---|
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
[Clinical studies on panipenem/betamipron in pediatrics].
Topics: Acute Disease; Adolescent; Age Factors; Bacteria; beta-Alanine; Child; Child, Preschool; Drug Evalua | 1992 |
8 other studies available for beta-alanine and Acute Disease
| Article | Year |
|---|---|
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
Topics: Accidental Falls; Acute Disease; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzim | 2013 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2014 |
Dabigatran-associated spontaneous acute cervical epidural hematoma.
Topics: Acute Disease; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cervical Vertebrae; Dabigatran; He | 2015 |
Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?
Topics: Acute Disease; Aged; Benzimidazoles; beta-Alanine; Dabigatran; Decision Making; Fibrinolytic Agents; | 2015 |
Activated β
Topics: Acute Disease; Animals; beta-Alanine; CD18 Antigens; Cytoskeletal Proteins; Lung; Mice, Inbred C57BL | 2017 |
Analgesic properties of the novel amino acid, isovaline.
Topics: Acute Disease; Analgesics, Non-Narcotic; Animals; beta-Alanine; Chronic Disease; Cisterna Magna; Fem | 2010 |
Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran.
Topics: Acute Disease; Antithrombins; Benzimidazoles; beta-Alanine; Carpal Tunnel Syndrome; Dabigatran; Deco | 2012 |
[Case of melioidosis associated with acute empyema and cellulitis of the leg].
Topics: Acute Disease; Aged; beta-Alanine; Burkholderia pseudomallei; Cellulitis; Clindamycin; Drug Therapy, | 1999 |